ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

26,476Medicare Part D Prescriptions Filled, Including Refills

Rank: 21 out of 1000

$1.15M Total Retail Price of All Prescriptions

Rank: 30 out of 1000

1,362 Patients Receiving at Least One Drug in Part D
71%Patients 65 Years and Older
64% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Alabama
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 1,362 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

29% of this provider’s 1,362 patients filled at least one prescription for a schedule three drug, compared to an average of 20%.

Risky Drugs to Seniors

4% of this provider’s 19,615 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$43 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Alabama
HYDROCODONE-ACETAMINOPHEN 2,025 1,272 S3 1 1
SIMVASTATIN 902 680 2 3
AMLODIPINE BESYLATE 850 686 3 6
OMEPRAZOLE 825 644 4 2
TRAMADOL HCL 746 500 5 13
LEVOTHYROXINE SODIUM 740 626 6 4
LISINOPRIL-HYDROCHLOROTHIAZIDE 717 513 7 20
LISINOPRIL 655 477 8 5
CLONIDINE HCL 571 508 9 27
METFORMIN HCL 489 345 10 8
ATORVASTATIN CALCIUM 345 246 11 18
LOSARTAN-HYDROCHLOROTHIAZIDE 322 244 12 38
MELOXICAM 316 249 13 14
ATENOLOL 307 223 14 24
BUMETANIDE 298 231 15 112
GLIMEPIRIDE 296 238 16 34
HYDRALAZINE HCL 294 257 17 74
FUROSEMIDE 287 238 18 7
METOPROLOL TARTRATE 279 256 19 19
VERAPAMIL ER 274 253 20 86
GABAPENTIN 264 202 21 11
PANTOPRAZOLE SODIUM 263 186 22 28
HYDROCHLOROTHIAZIDE 262 170 23 9
POTASSIUM CHLORIDE 256 196 24 10
WARFARIN SODIUM 249 228 25 22
NEXIUM 245 161 26 23
SERTRALINE HCL 236 170 27 26
PRAVASTATIN SODIUM 230 178 28 12
CYCLOBENZAPRINE HCL 205 117 R 29 39
AMITRIPTYLINE HCL 205 153 R 29 45
CIPROFLOXACIN HCL 204 152 31 46
MECLIZINE HCL 199 164 32 80
AZITHROMYCIN 199 141 32 36
LOSARTAN POTASSIUM 195 150 34 25
SPIRIVA 193 150 35 64
METOPROLOL SUCCINATE 187 147 36 21
TRAZODONE HCL 186 145 37 29
LEVOFLOXACIN 185 134 38 73
CLOPIDOGREL 181 149 39 35
AMOXICILLIN 179 122 40 89
CEFUROXIME 172 117 41 133
PROAIR HFA 172 91 41 50
ACTOPLUS MET 168 136 43 319
TAMSULOSIN HCL 167 120 44 33
PROMETHAZINE HCL 159 71 R 45 54
CARVEDILOL 155 98 46 15
ZOLPIDEM TARTRATE 153 113 47 16
DICLOFENAC SODIUM 152 116 48 123
CRESTOR 145 125 49 30
VENTOLIN HFA 145 105 49 83
INDOMETHACIN 145 104 R 49 246
RANITIDINE HCL 139 120 52 37
SINGULAIR 136 93 53 84
DOXEPIN HCL 132 97 54 176
PLAVIX 124 101 55 49
NOVOLIN 70-30 120 108 56 160
GLIPIZIDE ER 115 93 57 106
ALENDRONATE SODIUM 115 111 57 57
BYSTOLIC 113 101 59 126
FLUTICASONE PROPIONATE 109 93 60 40
METHOCARBAMOL 105 62 R 61 79
LIPITOR 101 66 62 170
FLUOXETINE HCL 99 43 63 51
DOXYCYCLINE HYCLATE 98 40 64 97
DIOVAN HCT 98 80 64 96
TRIAMCINOLONE ACETONIDE 96 71 66 159
HUMULIN 70-30 96 78 66 131
GLIPIZIDE XL 94 77 68 138
ALLOPURINOL 94 58 68 31
CEFDINIR 91 55 70 122
ZETIA 90 88 71 95
PREDNISONE 88 72 72 42
ACTOS 88 70 72 119
PHENYTOIN SODIUM EXTENDED 87 48 74 115
METOCLOPRAMIDE HCL 86 62 75 99
SYMBICORT 84 50 76 149
KLOR-CON M20 84 79 76 66
LANTUS SOLOSTAR 83 48 78 120
DONEPEZIL HCL 83 83 78 32
ISOSORBIDE MONONITRATE ER 82 60 80 71
DIGOXIN 81 79 81 52
LEVETIRACETAM 80 36 82 128
DIOVAN 78 67 83 67
CITALOPRAM HBR 77 56 84 17
NAMENDA 76 76 85 43
ROPINIROLE HCL 75 51 86 82
CELEBREX 74 60 87 98
LYRICA 74 50 87 47
HYDROXYZINE HCL 74 47 R 87 153
INSULIN SYRINGE 71 56 90 93
AMLODIPINE BESYLATE-BENAZEPRIL 71 37 90 59
JANUVIA 70 60 92 85
MONTELUKAST SODIUM 70 48 92 132
CARISOPRODOL 69 24 R 94 72
METFORMIN HCL ER 69 48 94 44
FLUCONAZOLE 65 19 96 102
SULFAMETHOXAZOLE-TRIMETHOPRIM 64 36 97 70
ETODOLAC 64 48 97 152
NITROFURANTOIN MONO-MACRO 63 39 99 191
OXYBUTYNIN CHLORIDE 62 62 100 145
DETROL LA 61 49 101 208
PIOGLITAZONE-METFORMIN 60 43 R 102 413
NADOLOL 59 40 103 335
CEPHALEXIN 59 51 103 90
VALACYCLOVIR 57 40 105 376
MIRTAZAPINE 56 48 106 56
VYTORIN 56 46 106 201
POLYETHYLENE GLYCOL 3350 55 31 108 69
LANSOPRAZOLE 54 22 109 190
ADVAIR DISKUS 53 38 110 65
DILTIAZEM 24HR CD 53 49 110 136
NITROGLYCERIN PATCH 52 52 112 226
RAMIPRIL 52 52 112 77
PRAMIPEXOLE DIHYDROCHLORIDE 52 26 112 147
DIPHENOXYLATE-ATROPINE 52 29 112 274
PROPRANOLOL HCL 51 50 116 135
CYMBALTA 51 43 116 53
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 12, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.